Mazdutide: Dosage, Protocol, and Research Guide
Dual GLP-1/glucagon receptor agonist; approved in China, not in the US
Mechanism
Activates the GLP-1 and glucagon receptors, combining appetite suppression and glucose control with increased energy expenditure
Protocol at a glance
| Starting dose | 3mg |
|---|---|
| Maintenance dose | 4.5-6mg |
| Maximum dose | 6mg |
| Frequency | Weekly |
| Typical duration | Ongoing |
| Route | Subcutaneous |
| Injection site | Abdomen or thigh |
| Timing | Same day weekly |
Side effects
- GI effects common initially
- Injection site reactions
Contraindications
- Medullary thyroid carcinoma history
- Pancreatitis
Protocol notes
- Dual GLP-1/glucagon receptor agonist (not a triple agonist)
- Potentially superior weight loss
- Approved in China; not approved in the US
- Requires careful titration
- Monitor pancreatic enzymes
Research references
- Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. · PMID 36247927
- A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity · PMID 38092790
Frequently asked questions
What makes Mazdutide different from other GLP-1 agonists?
Mazdutide is a dual receptor agonist (GLP-1 and glucagon), not a single-pathway therapy. While many weight-loss peptides target only the GLP-1 receptor, mazdutide simultaneously activates the GLP-1 and glucagon receptors. This dual receptor activation is designed to produce maximal weight loss and glycemic control through coordinated effects across multiple metabolic pathways, potentially creating synergistic effects that single-receptor agonists cannot achieve.
What is the recommended Mazdutide dosing protocol?
Mazdutide treatment begins with a 3mg starting dose administered via subcutaneous injection once weekly. The maintenance dosing range is 4.5-6mg weekly, with a maximum dose of 6mg per week. Injections are administered at the same day each week, using either the abdomen or thigh as the injection site. Careful titration is essential, with dose adjustments based on tolerability and response to treatment.
What are the most common side effects of Mazdutide?
Gastrointestinal effects are common initially during mazdutide treatment, though they typically decrease as the body adapts to receptor activation. Injection site reactions—such as localized redness, swelling, or discomfort—may also occur. These side effects are generally manageable, particularly with proper titration and dose adjustment. Practitioners should monitor patients closely during the initial weeks of treatment.
Who should not use Mazdutide?
Mazdutide has no US label. By analogy with approved GLP-1 drugs, people with a personal or family history of medullary thyroid carcinoma or MEN 2, or a history of pancreatitis, should not use it without specialist advice. Additionally, pancreatic enzyme monitoring is recommended throughout mazdutide treatment to ensure safety during ongoing use. Consultation with a qualified healthcare provider is essential to determine individual suitability.
What evidence supports Mazdutide's effectiveness?
Mazdutide efficacy is supported by clinical trials including a phase 2 randomised controlled trial in Chinese overweight adults or adults with obesity, as well as additional safety and efficacy studies in similar populations. These investigations have provided data on metabolic outcomes and tolerability. Research demonstrates that Mazdutide is in clinical trials with findings suggesting potential for weight loss and improved glycemic control, though ongoing research continues to expand the evidence base.
How long does Mazdutide treatment typically last?
Mazdutide is designed for ongoing use, with no predetermined endpoint specified in treatment protocols. Duration is determined based on individual patient response, goals, and safety monitoring. Regular monitoring of pancreatic enzymes and assessment of tolerability help guide treatment continuation decisions. Practitioners will work with patients to establish appropriate treatment duration aligned with metabolic health objectives.
What monitoring is required during Mazdutide therapy?
Pancreatic enzyme monitoring is recommended throughout Mazdutide treatment to ensure safety. This monitoring is important given the mechanism of action and the need for clinical oversight during ongoing peptide use. Practitioners should also assess gastrointestinal side effects during initial titration and evaluate injection site reactions. Regular check-ins support optimal dosing and early identification of any safety concerns that may arise.
Is Mazdutide FDA-approved?
Mazdutide is not FDA-approved. It is approved in China and is in clinical trials elsewhere investigating its safety and efficacy profile. Any use of mazdutide should be for research purposes only, and only under the guidance of a licensed physician who can properly evaluate its appropriateness for individual circumstances. Individuals should consult qualified healthcare providers before considering mazdutide as part of any protocol.
Related peptides
More GLP-1 & Weight Loss peptides · All peptide guides · All comparisons · Free dose calculator
Educational reference only — not medical advice. Work with a qualified clinician.